Evidence map›Paper›PMID 41651541›Full record

ArticleBMJ case reports2026

Disseminated

Nicholas William Dunstan, James Owen Robinson, Andrew Walczak, Ammie Higgins, Meinolf Karthaus, Mihitha Hashara Ariyapperuma

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nicholas William DunstanRoyal Perth Hospital, Perth, Western Australia, Australia nicholas.dunstan@health.wa.gov.au.
James Owen RobinsonInfectious Diseases, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
Andrew WalczakInfectious Diseases, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
Ammie HigginsPathWest Laboratory Medicine, Nedlands, Western Australia, Australia.
Meinolf KarthausHaematology, Oncology and Palliative Care, MVZ Onkomedeor, Munich-Perlach, Bavaria, Germany.
Mihitha Hashara AriyapperumaMedical Oncology, Western Australia Country Health Service, Spencer Park, Western Australia, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitor immunotherapy enhances T cell activity against cancer cells but often leads to the immune system targeting healthy cells, causing 'immune-related adverse events' (irAEs). We report the case of a man in his 70s with metastatic melanoma being treated with ipilimumab and nivolumab. He presented with febrile neutropenia after lacerating a thumb on his compost bin. The neutrophil count only recovered once oral prednisolone was commenced, indicating a haematological irAE. A restaging Positron Emission Tomography scan revealed intramuscular ring-enhancing collections throughout his body, one of which was aspirated and cultured the fungus

Indexed as

IpilimumabMelanomaMycosesNeutropeniaNivolumabAntifungal AgentsHumansMaleVoriconazoleAntifungal AgentsIpilimumabNivolumabVoriconazoleFungal InfectionsHaematology (incl blood transfusion)Immune Checkpoint Inhibitors

Identifiers

PMID41651541
PMCPMC12887154

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.